Skip to main content
. 2015 Jul 23;2015(7):CD000371. doi: 10.1002/14651858.CD000371.pub6
Methods Cluster‐RCT
Method to adjust for clustering: cluster used as unit of analysis.
Cluster unit: urban slums
Average cluster size: 13.5
ICCs: not reported.
Length of follow‐up: 1.5 years
Participants All children living in endemic area
Number analysed for primary outcome: 124 slums randomized containing 1672 children
Age range/ mean age: 0.8 years
Inclusion criteria: clusters selected if they had functional community workers in slum areas of Lucknow; within each cluster, children recruited if aged between 0.5 and 1 year, on basis of survey register held by each worker of their particular area
Exclusion criteria: none stated
Interventions Multiple doses vs placebo
  1. Albendazole plus placebo: albendazole suspension (concentration not stated) (Zentel, SZB) every 6 months and 100,000 units of vitamin A every 6 months

  2. Placebo: 100,000 units of vitamin A every 6 months

Outcomes
  1. Mean weight post‐treatment

  2. Mean change in weight post‐treatment

  3. Mean height post‐treatment

  4. Mean change in height post‐treatment (not used due to question over quoted standard error)


Not included in review: stool smear for Ascaris prevalence on a subsample of the group; death rates
Notes Location: Lucknow, India
Community category: 3
Means of cluster means used in analysis. The results (weight gain) in the abstract differ from the text.
Source of funding: International Clinical Epidemiological Network (INCLEN) Inc, USA and Clinical Trials Unit (CTSU), Oxford, UK.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Cluster‐randomized trial, no further details.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection bias) All outcomes Unclear risk No details reported.
Incomplete outcome data (attrition bias) All outcomes Low risk Intention‐to‐treat (ITT) analysis; 13.9% lost to follow‐up in albendazole group and 16.2% in the placebo group. Inclusion of all randomized participants (number evaluable/number randomized): 83% (1672/2010).
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk Recruitment bias: unclear (Not known if children shift clinics in the light of the intervention)
Baseline imbalance: characteristics similar (low risk)
Loss of clusters: no loss reported (low risk)
Incorrect analysis: cluster adjusted (low risk)
Comparability with RCTs randomizing individuals: low